Details for Patent: 12,527,769

Which drugs does patent 12,527,769 protect, and when does it expire?

Patent 12,527,769 protects RADICAVA ORS and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 12,527,769

Title:	Pharmaceutical composition for oral administration of edaravone and method of administering same
Abstract:	A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
Inventor(s):	Hidetoshi Shimizu, Yoshinobu NAKAMARU, Yukiko NISHIMURA
Assignee:	Mitsubishi Chemical Group Corp , Shionogi Inc
Application Number:	US18/932,827
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,527,769
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 12,527,769

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Shionogi	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,527,769					TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS BY ADMINISTERING A LIQUID EDARAVONE COMPOSITION RELATIVE TO THE TIMING AND TYPE OF FOOD CONSUMPTION

International Family Members for US Patent 12,527,769

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	124062
Australia	2021380319
Australia	2025203773
Canada	3198014
China	116761601